NCCN Awards Grants to Study Enzalutamide as Mantle Cell Lymphoma Treatment

NCCN Awards Grants to Study Enzalutamide as Mantle Cell Lymphoma Treatment

The drug was approved in 2012 by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic castration resistant prostate cancer and is marketed in the U.S under the brand name Xtandi sold as capsules made by Medivation, …

(Visited 1 times, 1 visits today)
5
Like
Save

Comments

Comments are disabled for this post.